newsfilter
← Earnings
Earnings Releases·

Cartesian Therapeutics — Third Quarter 2026 Earnings Summary

  • Reported net loss narrowed to $11.5 million ($0.38/share) from $35.9 million ($1.38/share) in Q3 2025, with zero revenue for the quarter compared to $452,000 previously; cash and equivalents totaled $124.7 million, sufficient to fund operations through 2028.
  • Guidance remains on track for Phase 3 AURORA data readout in Q1 2027 and a Biologics License Application (BLA) filing in mid-2027, supported by additional Phase 2 TRITON and Phase 1/2 HELIOS data expected in the first half of 2027.
  • Secured $50 million in non-dilutive financing from K2 HealthVentures and raised $22.8 million year-to-date via at-the-market offerings to support clinical execution and commercial team expansion.
  • Long-term debt of $50.2 million was recorded as of September 30, 2026, while the contingent value rights liability decreased to $346.0 million from $392.1 million at year-end 2025.
Company
CARTESIAN THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology